By Fineline Cube United Laboratories International Holdings Ltd (HKG: 3933) announced today it has received tacit approval from China’s National Medical Products Administration (NMPA) to conduct clinical studies for its Category 1 drug candidate TUL108, a novel ultra-broad-spectrum β-lactamase inhibitor. The compound was previously authorized for clinical trials in the United States in January 2026.
Regulatory Milestone
| Parameter | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Tacit approval, Category 1 innovative drug |
| Product | TUL108 (ultra-broad-spectrum β-lactamase inhibitor) |
| Previous Approval | US FDA clinical trial authorization (January 2026) |
| Company | United Laboratories International Holdings Ltd (HKG: 3933) |
Drug Profile & Mechanism of Action
- Molecule: Novel ultra-broad-spectrum β-lactamase inhibitor
- Target Pathogens: Gram-negative and Gram-positive bacteria, including multidrug-resistant strains
- Key Indications: Complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), pulmonary infections, and bloodstream infections
- Combination Therapy: Demonstrates enhanced efficacy when combined with meropenem
- Innovation: Achieves full coverage against clinically challenging carbapenem-resistant Gram-negative bacteria
Antimicrobial Activity Profile
| Pathogen | Resistance Profile | Sensitivity with TUL108 + Meropenem |
|---|---|---|
| Escherichia coli | Carbapenem-resistant | High sensitivity |
| Klebsiella pneumoniae | Carbapenem-resistant | High sensitivity |
| Pseudomonas aeruginosa | Carbapenem-resistant | High sensitivity |
| Acinetobacter baumannii | Carbapenem-resistant | High sensitivity |
The combination of TUL108 with meropenem demonstrates comprehensive activity against the most problematic carbapenem-resistant Gram-negative pathogens, addressing a critical unmet need in the antimicrobial resistance crisis.
Market Context & Strategic Outlook
- Antimicrobial Resistance Crisis: WHO identifies antimicrobial resistance as one of the top 10 global public health threats, with limited treatment options for carbapenem-resistant infections
- Commercial Opportunity: The global anti-infective market for resistant Gram-negative pathogens is projected to exceed $5 billion by 2028
- Dual-Market Strategy: United Laboratories’ simultaneous development in both US and China positions the company to address the largest markets for novel antibiotics
- Regulatory Incentives: Both US and Chinese regulatory frameworks offer expedited pathways and market exclusivity for novel antibiotics addressing priority pathogens
- Healthcare Impact: Successful development could significantly reduce mortality rates associated with carbapenem-resistant infections, which currently exceed 40% in some settings
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and potential therapeutic benefits of TUL108. Actual results may differ materially due to risks inherent in clinical drug development, including safety findings, efficacy outcomes, and regulatory decisions.-Fineline Info & Tech